Pasithea Therapeutics Corp (KTTA)vsMerck & Company Inc (MRK)
KTTA
Pasithea Therapeutics Corp
$0.50
-1.96%
HEALTHCARE · Cap: $19.39M
MRK
Merck & Company Inc
$143.76
-0.14%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 13681460% more annual revenue ($66.57B vs $486,560). MRK leads profitability with a 4.8% profit margin vs 0.0%. KTTA earns a higher WallStSmart Score of 38/100 (F).
KTTA
Hold38
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KTTA.
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.76
$60.92 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 1498.0% year-over-year
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : KTTA
The strongest argument for KTTA centers on Price/Book, Revenue Growth, Altman Z-Score. Revenue growth of 1498.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : KTTA
The primary concerns for KTTA are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
KTTA profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
KTTA carries more volatility with a beta of 0.29 — expect wider price swings.
KTTA is growing revenue faster at 1498.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
KTTA scores higher overall (38/100 vs 36/100) and 1498.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Pasithea Therapeutics Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Pasithea Therapeutics Corp. The company is headquartered in Miami Beach, Florida.
Visit Website →Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?